Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
Alkem Laboratories launched NeuCeno (cenobamate) on September 16, 2026, for adult patients with partial-onset seizures. This medication is the first cenobamate available in India and is offered in strengths from 12.5 mg to 200 mg. Additionally, on September 8, 2026, the company launched Renocia ExoTM, described as India's first patented Ginsenoside Exosome-based hair growth serum, to strengthen its dermatology portfolio.
As of 12:49 IST on the day of the report, Alkem Laboratories Ltd was trading at ₹5297, up 2.36% for the day. However, over the last year, the stock has decreased by 3.33%. This compares to a 8.21% drop in the NIFTY and a more significant 17.44% drop in the Nifty Pharma index over the same period.
Alkem Laboratories appointed Dr. Shubhadeep Sinha as Senior Vice President, effective September 15, 2026. Dr. Sinha brings over 25 years of experience in areas including clinical development, medical affairs, and regulatory affairs.
As of September 18, 2026, key technical levels for Alkem Laboratories include immediate resistance at ₹5489.83 (0.43% higher) and support at ₹5419.17 (-0.87% lower). Further resistance is noted at ₹5502.80, while a significant support level is identified at ₹5297.00.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Upward price movement of 3.18 standard deviations recorded on 2026-09-18.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Latest complete financial results for Q4 FY2026 and comparative quarterly trends.
| Metric | Q4 FY2025-26(Latest) | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 | Q4 FY2024-25 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹3,603.32 crore | ₹3,736.82 crore | PEAK₹4,000.99 crore | ₹3,371.14 crore | ₹3,143.75 crore |
| Profit Before Tax | ₹422.85 crore | ₹781.20 crore | PEAK₹895.83 crore | ₹771.01 crore | ₹396.34 crore |
| Finance Costs | PEAK₹53.88 crore | ₹42.10 crore | ₹35.02 crore | ₹29.78 crore | ₹28.42 crore |
| Other Expenses | PEAK₹1,125.96 crore | ₹914.60 crore | ₹968.94 crore | ₹767.68 crore | ₹856.83 crore |
| Tax Expense | PEAK₹171.17 crore | ₹127.67 crore | ₹116.23 crore | ₹102.69 crore | ₹73.33 crore |
| Profit Loss For Period | ₹251.11 crore | ₹653.03 crore | PEAK₹779.11 crore | ₹667.91 crore | ₹322.39 crore |
Tax expense for the quarter was ₹171.17 crore, more than double the ₹73.33 crore recorded a year earlier and 34.1% above the prior quarter. This resulted in an effective tax rate of 40.5%, compared with 18.5% a year ago and 16.3% in Q3 FY2025–26. The year-on-year increase in tax expense totalled ₹97.84 crore, directly reducing the profit for the period.
Basic and diluted earnings per share were both ₹19.77, down 22.7% from ₹25.57 a year earlier and 62.8% from ₹53.19 in the preceding quarter. The movement aligns precisely with the net profit decline.
Exchange disclosures and regulatory announcements for Alkem Laboratories.
On September 16, 2026, Alkem Laboratories Limited announced the launch of NeuCeno (cenobamate), an anti-seizure medication for treating partial-onset seizures in adult patients, marking the first time cenobamate is available in India. The once-daily oral therapy is offered in six tablet strengths ranging from 12.5 mg to 200 mg and utilizes a dual mechanism of action targeting persistent sodium currents and GABA-A receptors. Clinical studies cited in the announcement indicated that adjunctive cenobamate achieved up to a 78% reduction in seizure frequency and seizure freedom in up to 30% of patients during the maintenance phase.
Alkem Laboratories Limited appointed Dr. Shubhadeep Sinha to a senior management position effective September 15, 2026. The appointment is for an indefinite term contingent upon continued employment and follows the disclosure requirements of SEBI LODR Regulations. Dr. Sinha brings over 25 years of experience in clinical development, medical affairs, and regulatory affairs.
Alkem Laboratories Limited appointed Dr. Shubhadeep Sinha as Senior Vice President, effective September 15, 2026, classifying him as Senior Management Personnel. The appointment term is stated as 1 year in the filing due to utility constraints, but the company clarified the contract duration is for as long as he remains employed. Dr. Sinha brings over 25 years of experience in clinical development, medical affairs, pharmacovigilance, regulatory affairs, and healthcare management.
On 8th September 2026, Alkem Laboratories Limited launched Renocia ExoTM, described as India's first patented Ginsenoside Exosome-based hair growth serum, a next-generation hair regeneration therapy. The product targets multiple biological processes in hair loss management, including follicular miniaturization, oxidative stress, and inflammation, and is free from alcohol, sulphates, silicones, parabens, and mineral oil. The launch strengthens Alkem's dermatology portfolio.
NAME(S)OF THE ACQUIRER AND ITS(PAC) : HDFC Mutual Fund
Alkem Laboratories Limited held its 52nd Annual General Meeting on August 27, 2026, where all six resolutions were approved by shareholders. Key outcomes included the adoption of audited financial statements for the fiscal year ended March 31, 2026, confirmation of interim and final dividends, and the re-appointment of directors Sandeep Singh, Sarvesh Singh, and Madhurima Singh (for a five-year term). Additionally, the meeting ratified the remuneration of Cost Auditor Suresh D. Shenoy, with voting results showing overwhelming approval across all items.
Alkem Laboratories Limited uploaded transcripts of its earnings call for the quarter ended June 30, 2026, to its website on August 20, 2026. The earnings call was concluded on August 14, 2026, at 5:20 PM IST. Prior intimation of the call was disclosed to the exchange on July 27, 2026.
On August 17, 2026, equity shareholders of Alkem Laboratories Limited approved the Scheme of Amalgamation with Adroit Biomed Limited under Sections 230 to 232 of the Companies Act, 2013, by a vote of 99.9999% in favor. The meeting, convened pursuant to an NCLT Mumbai order dated June 10, 2026, was held via video conferencing with remote e-voting conducted from August 12 to August 16, 2026. Scrutinizer Mr. Ritul Parmar validated the results, which included 63,615,533 votes cast in favor out of 63,616,370 total votes polled.
Recent market and company developments associated with Alkem Laboratories.
Powered by Capital Market - Live News
The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction.
Alkem Laboratories Ltd is quoting at Rs 5297, up 2.36% on the day as on 12:49 IST on the NSE. The stock is down 3.33% in last one year as compared to a 8.21% drop in NIFTY and a 17.44% drop in the Nifty Pharma index.
Alkem Laboratories has launched NeuCeno (cenobamate) in India for adult patients with partial-onset seizures, available in strengths from 12.5 mg to 200 mg.
The key equity benchmarks ended higher on Wednesday, snapping a two-session losing streak. Gains followed a pause in crude oil prices and a marginal easing in global bond yields.
As per provisional closing data, the barometer index, the S&P BSE Sensex jumped 332.63 points or 0.45% to 74,336.45. The Nifty 50 index added 99 points or 0.43% to 23,217.60. In the past two consecutive trading sessions the Sensex and Nifty declined 1.20% and 1.53%, respectively.
The benchmark indices traded near the day's high in afternoon trade, tracking positive cues from Asian markets as the recent rally in crude oil prices paused. Investors remained cautious ahead of the US Federal Reserves policy meeting later today. The Nifty surged above the 23,250 mark, indicating some recovery in market sentiment.
Alkem Laboratories has announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients.
Comprehensive Section Breakdown for Alkem Laboratories
Strategic Vision: Multinational pharmaceutical company developing, manufacturing, and selling pharmaceutical products.
• Integrated operations across R&D, API synthesis, formulation manufacturing, and distribution.
• Diversified business model balancing domestic and international markets.
• Strong presence in key therapeutic segments.
• Regulatory compliance with global agencies.
In the fourth quarter of FY2025–26, Alkem Laboratories reported a 14.6% year-on-year increase in revenue, but net profit fell 22.1%. The decline was driven by a sharp rise in other operating expenses, sustained growth in finance costs, and a substantially higher tax charge. Both revenue and profit also declined sequentially from the preceding quarter, with the drop in net profit particularly steep.
Revenue from operations stood at ₹3,603.32 crore, up from ₹3,143.75 crore a year earlier and down from ₹3,736.82 crore in the prior quarter. Profit before tax came in at ₹422.85 crore, an increase of 6.7% year-on-year but a decrease of 45.9% sequentially. Net profit fell to ₹251.11 crore, marking a 22.1% year-on-year decline and a 61.5% sequential drop. The divergence between top-line growth and bottom-line contraction defines the quarter’s financial result.
Total expenses, calculated as revenue plus other income minus profit before tax, amounted to ₹3,380.54 crore. The sum of five disclosed cost categories—cost of materials consumed (₹894.94 crore), employee benefit expense (₹712.10 crore), finance costs (₹53.88 crore), depreciation (₹105.76 crore), and other expenses (₹1,125.96 crore)—totalled ₹2,892.64 crore. The remaining ₹487.90 crore, representing 14.4% of total expenses, is attributable to other cost items not explicitly broken out in the company’s quarterly reporting.
Other expenses, the largest single category, rose 31.4% year-on-year and 23.1% sequentially, growing faster than revenue and directly limiting profit expansion. Finance costs have risen for five consecutive quarters, reaching ₹53.88 crore, an 89.6% increase over the prior-year quarter and a 28.0% sequential rise. Cost of materials consumed accounted for 24.8% of revenue, employee benefits for 19.8%, and depreciation for 2.9%.
In Q4 FY2025–26, a sharp increase in other operating expenses, rising finance costs, and an elevated effective tax rate combined to push net profit 22.1% lower year-on-year, despite a 14.6% increase in revenue. The sequential fall was even steeper, with net profit declining 61.5% from the preceding quarter. The quarter’s performance highlights how rapid expense growth and higher tax charges can offset top-line gains, resulting in a significant contraction in reported earnings.
Category: B2B Services
Focuses on branded generic formulations across various acute and chronic therapeutic areas.
Category: B2B Services
A trade generics division catering to domestic market segments, comprising sub-divisions such as Futura, Maxxio, and Novokem.
Key Products & Services: Futura • Maxxio • Novokem
Category: Manufacturing
Handled by the Alkem Activa division, which synthesizes APIs for captive consumption and commercial supply.
Key Products & Services: Alkem Activa
Category: Consumer Tech
Develops biosimilars through its subsidiary Enzene Biosciences, alongside medical technology solutions in cardiology and orthopedics.
Key Products & Services: Enzene Biosciences
Core Thesis: The company balances acute therapy portfolios in domestic markets with global generic and specialty drugs, operating across the entire value chain from R&D to distribution.
• Diversified Business Model: Operates a diversified business model balancing acute therapy portfolios in domestic markets with generic and specialty drugs globally. • Value Chain Integration: Operates throughout the value chain, from R&D and API synthesis to large-scale formulation manufacturing and international distribution. • Therapeutic Area Focus: Maintains a strong therapeutic presence in Anti-Infectives, Gastroenterology, Cardiology, Neurology, Dermatology, Diabetology, and Pain Management. • Global and Domestic Presence: Maintains an international operating footprint, with the United States as its primary international market, alongside operations in Europe, Australia, Latin America, and emerging markets.